Trial Profile

This is a large real-world cohort study comparing the characteristics of multiple sclerosis patients treated with natalizumab (NTZ) vs. ocrelizumab/rituximab

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Oct 2021 Results assessing IgG immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
22 Apr 2021 Results (n=164) of subgroup assessing changes in the quality of life in neurological disorders questionnaire after natalizumab initiation and comparing with ocrelizumab, presented at the 73rd Annual Meeting of the American Academy of Neurology
22 Jan 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com